Dr Charles de Bock

Tabs

Main

My area of specialty lies in the genetics of acute lymphoblastic leukemia. I am particularly interested in how different mutations drive and maintain disease with a view to translate these finding into improved patient outcomes

I am primarily a molecular and cellular biologist with over 10 years’ experience performing research on haematological malignancies including 6 years post-doctoral training at the VIB/KU Leuven, Belgium.

I have led innovative research projects generating novel mouse models of leukemia that have resulted in publications within leading international journals (e.g. Cancer Discovery, Blood, Leukemia, Science Translational Medicine and Cancer Cell)

Through my research, teaching, and supervision of students, my aim is to train the next generation of scientists to make a long-lasting impact on paediatric cancer outcomes.

Please feel free to reach out to enquire about potential PhD and Post-doctoral opportunites.

School:

Sch Women's&Children's Health

Email:

cdebock@ccia.org.au

University role:

Team Leader, Functional Genomics of Leukaemia, Children's Cancer Institute

Qualifications:

2006           PhD (Cancer Biology), University of New South Wales, Australia
2000           MSc (Medical Science), First Class, University of Auckland, New Zealand
1998           BSc (Pharmacology), University of Auckland, New Zealand

Awards:

2017   Technology transfer and the exploitation of research, KU Leuven. Team awarded 1st place for exploitation plan.
2008   New South Wales (NSW) Office of Science and Medical Research Award for Best Postdoctoral Oral Presentation; ASMR NSW Meeting.
2004   St George Hospital Clinical School “Young Investigator of the Year”
1998   Fowlds Memorial Prize for most distinguished student in the Medicine and Health Science Faculty, University of Auckland, New Zealand
1997   Senior Prize in Pharmacology, University of Auckland, New Zealand

Keywords:

acute lymhoblastic leukaemia

oncology

genetic mouse model

genetics

Research

Research activities:

Personalised anti-cancer therapies have the potential to transform cancer treatments.

We now appreciate that at diagnosis, patients with T-cell leukaemia have more than 10 mutations. Some of these mutations will be sufficient to cause leukaemia, but the role of the majority of these mutations remains unknown.

My research program is focussed on defining the functional role for mutations found in T-cell acute lymphoblastic leukaemia. We utilise a “functional genomics” approach, that is creating in vitro and in vivo mouse models of T-cell leukaemia using clinically relevant mutations, to identify the key proteins and signalling pathways that should be targeted to control the disease.

This knowledge on which proteins and mutations are essential to drive the growth and survival of leukaemia cells will significantly improve our ability to use targeted agents based on an individual’s mutation signature.

Socio-economic Objective (SEO) tags:

Cancer and Related Disorders

Field of Research (FOR) Tag:

Oncology and Carcinogenesis

Haematological Tumours

Cancer Genetics

Teaching & Supervision

I am available to supervise:

Yes

Areas of supervision:

Currently, I have several projects for enthusiastic, motivated and passionate Honours, ILP or Ph.D. students in 2021. Feel free to reach out should any of these appeal to you.

(1) Long read sequencing to characterize the alternatively spliced transcriptome downstream of mutant JAK3 signaling in T-cell acute lymphoblastic leukemia.

In this project we will be using nanopore sequencing technology to look at the spliceosome in patients derived xenograft samples that harbour mutations in the IL7-JAK-STAT signaling pathway. Novel splice isoforms will then be modeled using our in vivo bone marrow transplant model system to determine their role in the maintenance and progression of the disease.

(2) Epigenetic profiling and eradication of relapse-initiating cells in paediatric acute lymphoblastic leukaemia

This project will investigate the following Hypotheses: (1) epigenetic modifications in subpopulations of ALL cells in the bone marrow provide a survival advantage during exposure to chemotherapy in vivo resulting in relapse; (2) Reversing these epigenetic aberrations will eradicate drug-resistant ALL cells and prevent relapse.

(3) The role of the FAT1 cadherin in Acute Lymphoblastic Leukaemia.

In this project, we will investigate targeting FAT1 cadherin positive acute lymphoblastic leukaemia with novel nanoparticles loaded with chemotherapeutics. The molecular role of FAT1 will also be investigated with respect to protecting cells from cell death, cellular homing in vivo and role in metabolism.

Media

LinkedIn:

https://www.linkedin.com/in/charles-de-bock-b521a268/

Twitter Account:

https://twitter.com/charles_debock

Publications related to this Person

Journal articles

Murray HC; Enjeti AK; Kahl RGS; Flanagan HM; Sillar J; Skerrett-Byrne DA; Al Mazi JG; Au GG; de Bock CE; Evans K; Smith ND; Anderson A; Nixon B; Lock RB; Larsen MR; Verrills NM; Dun MD, 2020, 'Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia', Leukemia, http://dx.doi.org/10.1038/s41375-020-01050-y

Broux M; Prieto C; Demeyer S; Bempt MV; Alberti-Servera L; Lodewijckx I; Vandepoel R; Mentens N; Gielen O; Jacobs K; Geerdens E; Vicente C; De Bock CE; Cools J, 2019, 'Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia', Blood, vol. 134, pp. 1323 - 1336, http://dx.doi.org/10.1182/blood.2019000015

Ahmed AF; de Bock CE; Sontag E; Hondermarck H; Lincz LF; Thorne RF, 2019, 'FAT1 cadherin controls neuritogenesis during NTera2 cell differentiation', Biochemical and Biophysical Research Communications, vol. 514, pp. 625 - 631, http://dx.doi.org/10.1016/j.bbrc.2019.04.197

de Bock CE; Down M; Baidya K; Sweron B; Boyd AW; Fiers M; Burns GF; Molloy TJ; Lock RB; Soulier J; Taghon T; Van Vlierberghe P; Cools J; Holst J; Thorne RF, 2019, 'T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development', Haematologica, vol. 104, pp. e204 - e207, http://dx.doi.org/10.3324/haematol.2018.198424

Habets RA; De Bock CE; Serneels L; Lodewijckx I; Verbeke D; Nittner D; Narlawar R; Demeyer S; Dooley J; Liston A; Taghon T; Cools J; De Strooper B, 2019, 'Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition', Science Translational Medicine, vol. 11, http://dx.doi.org/10.1126/scitranslmed.aau6246

Verboom K; Van Loocke W; Volders PJ; Decaesteker B; Avila Cobos F; Bornschein S; De Bock CE; Kalender Atak Z; Clappier E; Aerts S; Cools J; Soulier J; Taghon T; Van Vlierberghe P; Vandesompele J; Speleman F; Durinck K, 2018, 'A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing', Haematologica, vol. 103, pp. e585 - e589, http://dx.doi.org/10.3324/haematol.2018.190587

Baens M; Stirparo R; Lampi Y; Verbeke D; Vandepoel R; Cools J; Marynen P; de Bock CE; Bornschein S, 2018, 'Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice', European Journal of Immunology, vol. 48, pp. 1728 - 1738, http://dx.doi.org/10.1002/eji.201847597

Vicente C; Stirparo R; Demeyer S; De Bock CE; Gielen O; Atkins M; Yan J; Halder G; Hassan BA; Cools J, 2018, 'The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer models', Journal of Hematology and Oncology, vol. 11, http://dx.doi.org/10.1186/s13045-018-0650-0

Vanden Bempt M; Demeyer S; Broux M; De Bie J; Bornschein S; Mentens N; Vandepoel R; Geerdens E; Radaelli E; Bornhauser BC; Kulozik AE; Meijerink JP; Bourquin JP; de Bock CE; Cools J, 2018, 'Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia', Cancer Cell, vol. 34, pp. 271 - 285.e7, http://dx.doi.org/10.1016/j.ccell.2018.07.007

de Bock CE; Cools J, 2018, 'JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia', Molecular and Cellular Oncology, vol. 5, http://dx.doi.org/10.1080/23723556.2018.1458014

de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Bempt MV; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J, 2018, 'HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development', Cancer Discovery, vol. 8, pp. 616 - 631, http://dx.doi.org/10.1158/2159-8290.CD-17-0583

Bornschein S; Demeyer S; Stirparo R; Gielen O; Vicente C; Geerdens E; Ghesquière B; Aerts S; Cools J; De Bock CE, 2018, 'Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system', Leukemia, vol. 32, pp. 941 - 951, http://dx.doi.org/10.1038/leu.2017.328

Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD, 2018, 'Correction to: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia (Leukemia, (2018), 32, 3, (788-800), 10.1038/leu.2017.276)', Leukemia, vol. 32, pp. 2731, http://dx.doi.org/10.1038/s41375-018-0241-7

Degryse S; De Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD, 2018, 'Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia', Leukemia, vol. 32, pp. 788 - 800, http://dx.doi.org/10.1038/leu.2017.276

Degryse S; Bornschein S; De Bock CE; Leroy E; Bempt MV; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J, 2018, 'Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL', Blood, vol. 131, pp. 421 - 425, http://dx.doi.org/10.1182/blood-2017-07-797597

Pajic M; Froio D; Daly S; Doculara L; Millar E; Graham PH; Drury A; Steinmann A; De Bock CE; Boulghourjian A; Zaratzian A; Carroll S; Toohey J; O'Toole SA; Harris AL; Buffa FM; Gee HE; Hollway GE; Molloy TJ, 2018, 'miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense', Cancer Research, vol. 78, pp. 501 - 515, http://dx.doi.org/10.1158/0008-5472.CAN-16-3105

de Bock CE; Hughes MR; Snyder K; Alley S; Sadeqzadeh E; Dun MD; McNagny KM; Molloy TJ; Hondermarck H; Thorne RF, 2017, 'Protein interaction screening identifies SH3RF1 as a new regulator of FAT1 protein levels', FEBS Letters, vol. 591, pp. 667 - 678, http://dx.doi.org/10.1002/1873-3468.12569

Dagklis A; Demeyer S; DeBie J; Radaelli E; Pauwels D; Degryse S; Gielen O; Vicente C; Vandepoel R; Geerdens E; Uyttebroeck A; Boeckx N; De Bock CE; Cools J, 2016, 'Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors', Blood, vol. 128, pp. 2642 - 2654, http://dx.doi.org/10.1182/blood-2016-03-703454

De Bock CE; Thorne RF, 2016, 'A mitochondrial brake on vascular repair', Nature, vol. 539, pp. 503 - 505, http://dx.doi.org/10.1038/nature20476

Vanden Bempt M; Demeyer S; Mentens N; Geerdens E; De Bock CE; Wlodarska I; Cools J, 2016, 'Generation of the Fip1l1-Pdgfra fusion gene using CRISPR/Cas genome editing', Leukemia, vol. 30, pp. 1913 - 1916, http://dx.doi.org/10.1038/leu.2016.62

Durinck K; Van Loocke W; Van Der Meulen J; Van De Walle I; Ongenaert M; Rondou P; Wallaert A; De Bock CE; Van Roy N; Poppe B; Cools J; Soulier J; Taghon T; Speleman F; Van Vlierberghe P, 2015, 'Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia', Leukemia, vol. 29, pp. 2317 - 2327, http://dx.doi.org/10.1038/leu.2015.162

Ahmed AF; De Bock CE; Lincz LF; Pundavela J; Zouikr I; Sontag E; Hondermarck H; Thorne RF, 2015, 'FAT1 cadherin acts upstream of Hippo signalling through TAZ to regulate neuronal differentiation', Cellular and Molecular Life Sciences, vol. 72, pp. 4653 - 4669, http://dx.doi.org/10.1007/s00018-015-1955-6

de Bock CE; Cools J, 2015, 'T-ALL: Home Is where the CXCL12 Is', Cancer Cell, vol. 27, pp. 745 - 746, http://dx.doi.org/10.1016/j.ccell.2015.05.011

Peirs S; Matthijssens F; Goossens S; Van De Walle I; Ruggero K; De Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P, 2014, 'ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia', Blood, vol. 124, pp. 3738 - 3747, http://dx.doi.org/10.1182/blood-2014-05-574566

Degryse S; De Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J, 2014, 'JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model', Blood, vol. 124, pp. 3092 - 3100, http://dx.doi.org/10.1182/blood-2014-04-566687

Sadeqzadeh E; De Bock CE; O'Donnell MR; Timofeeva A; Burns GF; Thorne RF, 2014, 'FAT1 cadherin is multiply phosphorylated on its ectodomain but phosphorylation is not catalysed by the four-jointed homologue', FEBS Letters, vol. 588, pp. 3511 - 3517, http://dx.doi.org/10.1016/j.febslet.2014.08.014

Oliveira CS; de Bock CE; Molloy TJ; Sadeqzadeh E; Geng XY; Hersey P; Zhang XD; Thorne RF, 2014, 'Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma', BMC Cancer, vol. 14, http://dx.doi.org/10.1186/1471-2407-14-630

Sadeqzadeh E; De Bock CE; Wojtalewicz N; Holt JE; Smith ND; Dun MD; Schwarte-Waldhoff I; Thorne RF, 2014, 'Furin processing dictates ectodomain shedding of human FAT1 cadherin', Experimental Cell Research, vol. 323, pp. 41 - 55, http://dx.doi.org/10.1016/j.yexcr.2014.02.012

Wojtalewicz N; Sadeqzadeh E; Weiß JV; Tehrani MM; Klein-Scory S; Hahn S; Schmiegel W; Warnken U; Schnölzer M; De Bock CE; Thorne RF; Schwarte-Waldhoff I, 2014, 'A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0090461

Sadeqzadeh E; De Bock CE; Thorne RF, 2014, 'Sleeping Giants: Emerging Roles for the Fat Cadherins in Health and Disease', Medicinal Research Reviews, vol. 34, pp. 190 - 221, http://dx.doi.org/10.1002/med.21286

Sadeqzadeh E; de Bock CE; O'Donnell MR; Timofeeva A; Burns GF; Thorne RF, 2014, 'FAT1 cadherin is multiply phosphorylated on its ectodomain but phosphorylation is not catalysed by the four-jointed homologue', FEBS Letters, http://dx.doi.org/10.1016/j.febslet.2014.08.014

Ardjmand A; de Bock CE; Shahrokhi S; Lincz LF; Boyd AW; Burns GF; Thorne RF, 2013, 'Fat1 cadherin provides a novel minimal residual disease marker in acute lymphoblastic leukemia', Hematology, vol. 18, pp. 315 - 322, http://dx.doi.org/10.1179/1607845413Y.0000000080

De Bock CE; Ardjmand A; Molloy TJ; Bone SM; Johnstone D; Campbell DM; Shipman KL; Yeadon TM; Holst J; Spanevello MD; Nelmes G; Stewart D; Lincz LF; Boyd AW; Burns GF; Thorne RF, 2012, 'The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia', Leukemia, vol. 26, pp. 918 - 926, http://dx.doi.org/10.1038/leu.2011.319

Dong L; Jiang CC; Thorne RF; Croft A; Yang F; Liu H; De Bock CE; Hersey P; Zhang XD, 2011, 'Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress', Oncogene, vol. 30, pp. 3716 - 3726, http://dx.doi.org/10.1038/onc.2011.87

Sadeqzadeh E; De Bock CE; Zhang XD; Shipman KL; Scott NM; Song C; Yeadon T; Oliveira CS; Jin B; Hersey P; Boyd AW; Burns GF; Thorne RF, 2011, 'Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products', Journal of Biological Chemistry, vol. 286, pp. 28181 - 28191, http://dx.doi.org/10.1074/jbc.M111.234419

De Bock CE; Garg MB; Scott N; Sakoff JA; Scorgie FE; Ackland SP; Lincz LF, 2011, 'Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo', Pharmacogenomics Journal, vol. 11, pp. 307 - 314, http://dx.doi.org/10.1038/tpj.2010.43

Thorne RF; Ralston KJ; de Bock CE; Mhaidat NM; Zhang XD; Boyd AW; Burns GF, 2010, 'Palmitoylation of CD36/FAT regulates the rate of its post-transcriptional processing in the endoplasmic reticulum', Biochimica et Biophysica Acta - Molecular Cell Research, vol. 1803, pp. 1298 - 1307, http://dx.doi.org/10.1016/j.bbamcr.2010.07.002

De Bock CE; Lin Z; Mekkawy AH; Byrne JA; Wang Y, 2010, 'Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion', International Journal of Oncology, vol. 36, pp. 1155 - 1163, http://dx.doi.org/10.3892/ijo-00000598

Mekkawy AH; De Bock CE; Lin Z; Morris DL; Wang Y; Pourgholami MH, 2010, 'Novel protein interactors of urokinase-type plasminogen activator receptor', Biochemical and Biophysical Research Communications, vol. 399, pp. 738 - 743, http://dx.doi.org/10.1016/j.bbrc.2010.08.010

Jiang CC; Lucas K; Avery-Kiejda KA; Wade M; DeBock CE; Thorne RF; Allen J; Hesey P; Zhang XD, 2008, 'Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress', Cancer Research, vol. 68, pp. 6708 - 6717, http://dx.doi.org/10.1158/0008-5472.CAN-08-0349

Mhaidat NM; Thorne RF; de Bock CE; Zhang XD; Hersey P, 2008, 'Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III β-tubulin levels', FEBS Letters, vol. 582, pp. 267 - 272, http://dx.doi.org/10.1016/j.febslet.2007.12.014

Tassabehji M; Fang ZM; McGaughran J; Zhao Z; De Bock CE; Howard E; Malass M; Donnai D; Diwan AD; Manson FD; Murrell DF; Clarke RA, 2008, 'Mutations in GDF6 are associated with vertebral segmentation defects in klippel-feil syndrome', Human Mutation, vol. 29, pp. 1017 - 1027, http://dx.doi.org/10.1002/humu.20741

Molloy TJ; De Bock CE; Wang Y; Murrell GA, 2006, 'Gene expression changes in SNAP-stimulated and iNOS-transfected tenocytes-expression of extracellular matrix genes and its implications for tendon-healing', Journal of Orthopaedic Research, vol. 24, pp. 1869 - 1882, http://dx.doi.org/10.1002/jor.20237

De Bock CE; Lin Z; Itoh T; Morris DL; Murrell GA; Wang Y, 2005, 'Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells', FEBS Journal, vol. 272, pp. 3572 - 3582, http://dx.doi.org/10.1111/j.1742-4658.2005.04778.x

De Bock CE; Wang Y, 2004, 'Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer', Medicinal Research Reviews, vol. 24, pp. 13 - 39, http://dx.doi.org/10.1002/med.10054

Xia W; De Bock CE; Murrell GA; Wang Y, 2003, 'Expression of urokinase-type plasminogen activator and its receptor is up-regulated during tendon healing', Journal of Orthopaedic Research, vol. 21, pp. 819 - 825, http://dx.doi.org/10.1016/S0736-0266(03)00058-5

Gieseg MA; De Bock C; Turner P; Ferguson LR; Denny WA, 2002, 'The effect of DNA-alkylating agents on gene expression from two integrated reporter genes in a mouse mammary tumor line', Anti-Cancer Drugs, vol. 13, pp. 271 - 280, http://dx.doi.org/10.1097/00001813-200203000-00009

Gieseg MA; De Bock C; Ferguson LR; Denny WA, 2001, 'Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033', Anti-Cancer Drugs, vol. 12, pp. 683 - 690, http://dx.doi.org/10.1097/00001813-200109000-00007

Conference Papers

Bempt MV; de Bock CE; Demeyer S; Vandepoel R; Mentens N; Geerdens E; Radaelli E; Cools J, 2016, 'THE NUP214-ABL1 FUSION COOPERATES WITH TLX1 IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, Copenhagen, DENMARK, pp. 27 - 27, presented at 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, 09 June 2016 - 12 June 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000379484600057&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Durinck K; Vanloocke W; Van der Meulen J; de Walle IV; Rondou P; De Bock C; Verhasselt B; Poppe BG; Cools J; Soulier J; Taghon T; Speleman F; Van Vlierberghe P, 2014, 'Transcriptional Antagonism Between the Cooperative Oncogenes TLX1 and NOTCH1 in T-Cell Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, San Francisco, CA, presented at 56th Annual Meeting of the American-Society-of-Hematology, San Francisco, CA, 06 December 2014 - 09 December 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349233806079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Vanden M; de Bock CE; Mentens N; Gielen O; Geerdens E; Demeyer S; Cools J, 2014, 'Use of Crispr/Cas Genome Editing in Ba/F3 Cells to Generate the Fip1l1-Pdgfra and Nup214-Abl1 Fusion Genes', in BLOOD, AMER SOC HEMATOLOGY, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242707124&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sandrine D; de Bock CE; Vicente C; Cox L; Gielen O; Mentens N; Jacobs K; Geerdens E; Tousseyn T; Cools J, 2014, 'JAK3 Mutants Transform Hematopoietic Cells through JAK1 Activation Causing T-Cell Acute Lymphoblastic Leukemia in a Bone Marrow Transplant Mouse Model', in BLOOD, AMER SOC HEMATOLOGY, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242706130&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

de Bock CE; Degryse S; Demeyer S; Sweron B; Gielen O; Mentens N; Geerdens E; Cools J, 2014, 'Synergism Between HOXA9 and Mutant JAK3 (M511I) Leads to Rapid Leukemia Development within an in Vivo Murine Bone Marrow Transplant Model', in BLOOD, AMER SOC HEMATOLOGY, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242706111&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Durinck K; Van Loocke W; Van der Meulen J; Van de Walle I; Rondou P; De Bock CE; Poppe B; Cools J; Soulier J; Taghon T; Speleman F; Van Vlierberghe P, 2014, 'Transcriptional antagonism between the cooperative oncogenes TLX1 and NOTCH1 in T-cell acute lymphoblastic leukemia.', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, presented at AACR Special Conference on Hematologic Malignancies - Translating Discoveries to Novel Therapies, Philadelphia, PA, 20 September 2014 - 23 September 2014, http://dx.doi.org/10.1158/1557-3265.HEMMAL14-B05

Peirs S; Matthijssens F; Goossens S; De Bock C; Cante-Barrett K; Lammens T; Van de Walle I; De Moerloose B; Benoit Y; Poppe B; Taghon T; Cools J; Meijerink J; Soulier J; Speleman F; Van Vlierberghe P, 2014, 'ABT-199 MEDIATED INHIBITION OF BCL2 AS A NOVEL THERAPEUTIC STRATEGY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, Milan, ITALY, pp. 539 - 540, presented at 19th Congress of the European-Hematology-Association, Milan, ITALY, 12 June 2014 - 15 June 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342830902361&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Durinck K; Rondou P; de Walle IV; De Bock C; Van Roy N; Benoit Y; Poppe B; Taghon T; Soulier J; Cools J; Van Vlierberghe P; Speleman F, 2014, 'PHF6 LOSS DRIVES IL7R ONCOGENE ADDICTION IN T-ALL', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, Milan, ITALY, pp. 1 - 1, presented at 19th Congress of the European-Hematology-Association, Milan, ITALY, 12 June 2014 - 15 June 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342830900003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

de Bock C; Boyd A; Burn G; Cools J; Thorne R, 2013, 'A UNIQUE FAT1 CADHERIN ISOFORM REGULATES THE PROLIFERATION OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) CELLS', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, pp. 4 - 4, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000445772400011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Degryse S; Cox L; Gianfelici V; Gielen O; Mentens N; Jacobs K; De Bock C; Cools J, 2013, 'THE ROLE OF JAK3 MUTATIONS IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: DEVELOPMENT OF IN VITRO AND IN VIVO MODELS', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, pp. 467 - 467, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000445782800165&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sadeqzadeh E; Hersey P; Zhang XD; deBock C; Boyd A; Burns G; Thorne R, 2011, 'Aberrant processing of Fat1 Cadherin in human cancer', in CLINICAL BIOCHEMISTRY, PERGAMON-ELSEVIER SCIENCE LTD, pp. S12 - S12, http://dx.doi.org/10.1016/j.clinbiochem.2011.08.037

Wang Y; Lin Z; Mekkawy AH; De Bock CE, 2008, 'Interaction between urokinase receptor and heat shock protien enhances cell adhesion', in Challenges to Life Sciences: Molecules and cells, 9th International Congress on Cell Biology, Seoul, Korea, pp. 258 - 258, presented at 9th International Congress on Cell Biology, Seoul, Korea, 07 October 2008 - 10 October 2008

Conference Abstracts

Loontiens S; Durinck K; Vanhauwaert S; Depestel L; Oliveira ML; Dewyn G; De Bock C; Barata JT; Langenau D; Cools J; Taghon T; Van Vlierberghe P; Speleman F, 2019, 'PHF6loss drives IL7R oncogene addiction in TLX1 driven T-ALL', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3696

Other

de Bock C, 2016, Measures of success Reply, AMER ASSOC ADVANCEMENT SCIENCE, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373039600052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Barz CS; Benford ME; Mishra MK; Chia TS; Cooper E; Newton K; Bonel N; de Bock C; Farenhem K; Zupanc J; Elsanadidy E; Gopinath SD; Winter M; Kemp KC; Nieuwenhuis R; Hoyer JS; Li R; Lindsay G; Li D; O'Mullane A; Schuenemann KC; Ramirez D; Yu SS; Pun M; Li CY, 2016, Measures of success, AMER ASSOC ADVANCEMENT SCIENCE, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373039600017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

School of Women's and Children's Health

Dr Charles de Bock

Tabs

Study @ WCH

Research @ WCH

Quick Links

Connect